Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)
JNCI: Journal of the National Cancer Institute · 2025
DOI: 10.1093/jnci/djaf281 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von En Cheng und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States. Hauptthemen laut MEDLINE: Colonic Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Alliance for Clinical Trials in Oncology, Montefiore Einstein Comprehensive Cancer Center.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Completing adjuvant chemotherapy and reducing toxicities are critical for maximizing survival after a colon cancer diagnosis. Sex, as a biological variable, may affect colon cancer chemotherapy completion, toxicities, and survival differently.
Methods
From a National Cancer Institute–sponsored trial conducted among patients with stage III colon cancer (Cancer and Leukemia Group B (Alliance)/Southwest Oncology Group 80702), we included 2201 patients receiving the standard adjuvant chemotherapy regimen of fluorouracil, leucovorin, and oxaliplatin. We calculated relative dose intensity to indicate chemotherapy completion and considered reduced relative dose intensity (values <85%) as a clinically significant deviation from standard fluorouracil, leucovorin, and oxaliplatin. Using National Cancer Institute’s Common Terminology Criteria for Adverse Events, we defined severe adverse events (grade ≥3) as the occurrence of any following event, including neutrophil count decrease, nausea, platelet count decrease, hypertension, peripheral neuropathy, diarrhea, fatigue, gastritis, creatinine level increase, gastric ulcer, myocardial ischemia, and cerebral ischemia. The primary survival outcome was disease-free survival (time from enrollment to colon cancer recurrence or death from any cause), and secondary survival outcomes were recurrence-free and overall survival.
Results
Compared with men, women were at statistically significantly higher risks of experiencing reduced relative dose intensity (adjusted odds ratio = 1.59, 95% CI = 1.29 to 1.96; P < .001) and severe advance events (adjusted odds ratio = 1.72, 95% CI = 1.41 to 2.11; P < .001). Yet, women had statistically significantly better disease-free survival (adjusted hazard ratio = 0.72, 95% CI = 0.59 to 0.87; P < .001) as well as better recurrence-free and overall survival.
Conclusions
Our findings suggested that women with colon cancer are more likely to have worse chemotherapy completion rates and more severe adverse events, but they have better survival. Sex as a biological variable warrants further consideration in chemotherapy administration and survivorship management after colon cancer diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, United States.
- Cancer Epidemiology, Prevention and Control Program, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, United States.
- Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, United States.
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States.
- Department of Oncology, Albert Einstein College of Medicine, Bronx, NY, United States.
- Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL, United States.
ORCID-Profile: En Cheng, Qian Shi, Anthony F Shields, Xiaonan Xue, Chaoyuan Kuang, Chao Ma, J Philip Kuebler, Pankaj Kumar, Smitha S Krishnamurthi, Kimmie Ng, Eileen M O'Reilly, Justin C Brown, Jeffrey A Meyerhardt
Förderung
- NCI NIH HHS
- Alliance for Clinical Trials in Oncology
- Montefiore Einstein Comprehensive Cancer Center
- Canadian Cancer Trials Group
- NCATS NIH HHS
- NRG Oncology
- Health and Environmental Sciences Institute
- SWOG Cancer Research Network
Zitieren
APA
Cheng, E., Shi, Q., Shields, A. F., Xue, X., Rohan, T. E., Kuang, C., Shergill, A. P., Ma, C., Couture, F., Kuebler, J. P., Kumar, P., Tan, B., Krishnamurthi, S. S., Ng, K., O'Reilly, E. M., Brown, J. C., & Meyerhardt, J. A. (2025). Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djaf281
Vancouver
Cheng E, Shi Q, Shields AF, Xue X, Rohan TE, Kuang C, et al. Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance). JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djaf281
BibTeX
@article{Cheng2025,
author = {Cheng, En and Shi, Qian and Shields, Anthony F and Xue, Xiaonan and Rohan, Thomas E and Kuang, Chaoyuan and Shergill, Ardaman P and Ma, Chao and Couture, Felix and Kuebler, J Philip and Kumar, Pankaj and Tan, Benjamin and Krishnamurthi, Smitha S and Ng, Kimmie and O'Reilly, Eileen M and Brown, Justin C and Meyerhardt, Jeffrey A},
title = {Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)},
journal = {JNCI: Journal of the National Cancer Institute},
year = {2025},
doi = {10.1093/jnci/djaf281}
}
EUVIMED